Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

Trial Profile

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anifrolumab (Primary) ; Glucocorticoids; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TULIP-LN; TULIP-LN1
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Nov 2023 Results (n=117) assessing untargeted metabolomics profiling on urine samples from the phase 2 trial to identify markers associated with LN disease activity that were modulated by anifrolumab, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results assessing unbiased metabolomic serum profiling to determine novel biomarkers of treatment response and provide insights into the mechanism of action of anifrolumab presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results (from two studies n=131 from NCT02547922 and n=59 from NCT02446912) hypothesizing that Renal Activity Index for Lupus (RAIL) is effective in distinguishing inactive vs active LN and can differentiate LN treatment responders from non-responders in adult patients presented at the ACR Convergence 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top